ARGIPRESSIN AOP

25ml to 1ml (5 to 20 units) by subcutaneous or intramuscular injection every four hours.

Oesophageal Varices:

For the initial control of variceal bleeding Argipressin AOP should be given intravenously. Argipressin AOP 20 units, diluted in 100ml dextrose 5% w/v, may be infused over a 15 minute period. Elderly (over 65 years) As for adults, no clinical or pharmacokinetic data specific to this age group are available.

However, the drug has been successfully used at normal dosage in the elderly. Paediatric population Not recommended in children below 18 years. Method of administration Subcutaneous, intravenous or intramuscular injection.

The following undesirable effects have been observed and reported during treatment with Argipressin with the following frequency: The undesirable effects are listed below by organ class and the following frequency convention: Very common: (≥1/10) Common: (≥1/100, <1/10) Uncommon: (≥1/1,000, <1/100) Rare: ((≥1/10,000, <1/1,000) Very rare: (<1/10,000), Not known – frequency cannot be estimated from the available data.

The frequency of the following side effects is not known. Immune system disorders • Hypersensitivity • anaphylaxis Metabolism and nutrition disorders • hyperhydration / water intoxication Nervous system disorders • headache • vertigo • tremor Cardiac disorder • chest pain due to angina • cardiac arrest Vascular disorders • peripheral ischaemia • pallor • hypertension Respiratory, thoracic and mediastinal disorders • bronchospasm Gastrointestinal disorders • flatulence • nausea • vomiting • diarrhoea • abdominal pain Skin and subcutaneous tissue disorders • gangrene • hyperhidrosis • urticaria Renal and urinary disorders • fluid retention General disorders and administration site conditions • non-cardiac chest pain Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk or search for MHRA Yellow Card in the Google Play or Apple App Store.

Argipressin should not be used in patients with systemic hypertension or vascular disease, especially disease of the coronary arteries, except with extreme caution. In such patients, even small doses may precipitate pain, and with larger doses, the possibility of myocardial infarction should be considered.

If this drug must be used in patients with peripheral vascular disease then the skin should be observed carefully for signs of ischaemia. Argipressin may produce water intoxication. The early signs of drowsiness, listlessness, and headaches should be recognised to prevent terminal coma and convulsions.

Adjustment of dosage in cases immediately post-hypophysectomy should be controlled on the basis of measurements of urine osmolality. Argipressin should be used cautiously in the presence of epilepsy, migraine, asthma, heart failure, or any state in which a rapid addition to extracellular water may produce hazard for an already overburdened system.

Chronic nephritis with nitrogen retention contraindicates the use of argipressin injection until reasonable nitrogen blood levels have been attained.

1. Patient with coronary artery disease, or those intended to receive halogenated anaesthetic agents. Vascular disease (especially disease of coronary arteries), chronic nephritis (until reasonable blood nitrogen concentrations attained).